Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/230334
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease |
Autor: | Podlesniy, Petar CSIC ORCID; Llorens, Franc; Puigros Serra, Margalida CSIC ORCID; Serra, Nuria CSIC; Sepúlveda-Falla, Diego; Schmidt, Christian; Hermann, Peter; Zerr, Inga; Trullas, Ramón CSIC ORCID | Palabras clave: | Mitochondrial DNA Cerebrospinal fluid Alzheimer’s disease Biomarkers Digital PCR |
Fecha de publicación: | 31-ago-2020 | Editor: | Molecular Diversity Preservation International | Citación: | International Journal of Molecular Sciences 21(17): 6298 (2020) | Resumen: | Alzheimer’s type dementia (AD) exhibits clinical heterogeneity, as well as differences in disease progression, as a subset of patients with a clinical diagnosis of AD progresses more rapidly (rpAD) than the typical AD of slow progression (spAD). Previous findings indicate that low cerebrospinal fluid (CSF) content of cell-free mitochondrial DNA (cf-mtDNA) precedes clinical signs of AD. We have now investigated the relationship between cf-mtDNA and other biomarkers of AD to determine whether a particular biomarker profile underlies the different rates of AD progression. We measured the content of cf-mtDNA, beta-amyloid peptide 1–42 (Aβ), total tau protein (t-tau) and phosphorylated tau (p-tau) in the CSF from a cohort of 95 subjects consisting of 49 controls with a neurologic disorder without dementia, 30 patients with a clinical diagnosis of spAD and 16 patients with rpAD. We found that 37% of controls met at least one AD biomarker criteria, while 53% and 44% of subjects with spAD and rpAD, respectively, did not fulfill the two core AD biomarker criteria: high t-tau and low Aβ in CSF. In the whole cohort, patients with spAD, but not with rpAD, showed a statistically significant 44% decrease of cf-mtDNA in CSF compared to control. When the cohort included only subjects selected by Aβ and t-tau biomarker criteria, the spAD group showed a larger decrease of cf-mtDNA (69%), whereas in the rpAD group cf-mtDNA levels remained unaltered. In the whole cohort, the CSF levels of cf-mtDNA correlated positively with Aβ and negatively with p-tau. Moreover, the ratio between cf-mtDNA and p-tau increased the sensitivity and specificity of spAD diagnosis up to 93% and 94%, respectively, in the biomarker-selected cohort. These results show that the content of cf-mtDNA in CSF correlates with the earliest pathological markers of the disease, Aβ and p-tau, but not with the marker of neuronal damage t-tau. Moreover, these findings confirm that low CSF content of cf-mtDNA is a biomarker for the early detection of AD and support the hypothesis that low cf-mtDNA, together with low Aβ and high p-tau, constitute a distinctive CSF biomarker profile that differentiates spAD from other neurological disorders. | Versión del editor: | https://doi.org/10.3390/ijms21176298 | URI: | http://hdl.handle.net/10261/230334 | DOI: | 10.3390/ijms21176298 | ISSN: | 1661-6596 | E-ISSN: | 1422-0067 |
Aparece en las colecciones: | (IIBB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
PODLESNIY P. open access Cerebrospinal fluid mitochondrial DNA in rapid ....pdf | 1,44 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
13
checked on 28-feb-2024
SCOPUSTM
Citations
14
checked on 17-abr-2024
WEB OF SCIENCETM
Citations
13
checked on 25-feb-2024
Page view(s)
93
checked on 24-abr-2024
Download(s)
25
checked on 24-abr-2024